Biocept Inc (BIOC): Edward A. Neff , director of Biocept Inc purchased 100,000 shares on May 4, 2016. The Insider buying transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were purchased at $1.00 per share for a total value of $100,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 5, 2016, Claire Reiss (10% owner) purchased 614,273 shares at $1.00 per share price.On May 5, 2016, Bruce Gerhardt (director) purchased 25,000 shares at $1.00 per share price.Also, On Jun 2, 2015, Veena Singh (Sr VP & Sr Med Director) purchased 5,000 shares at $3.08 per share price.On Feb 18, 2015, Margaret Faye Wilson (director) purchased 4,000 shares at $1.25 per share price.
Shares of Biocept Inc (BIOC) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.051 points or -5.36% at $0.9 with 3,15,932 shares getting traded. Post opening the session at $0.96, the shares hit an intraday low of $0.8819 and an intraday high of $0.9799 and the price vacillated in this range throughout the day. The company has a market cap of $18 M and the number of outstanding shares has been calculated to be 1,99,83,402 shares. The 52-week high of Biocept Inc is $3.7 and the 52-week low is $0.8819.
Biocept Inc. is a cancer diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) tests utilizing a standard blood sample. Its marketed tests are OncoCEE-BR for breast cancer CTC enumeration and analysis OncoCEE-GA for gastric cancer CTC enumeration and analysis and OncoCEE-LU for non-small cell lung cancer or NSCLC CTC enumeration and analysis. Its marketed test and the tests under development for the enumeration and analysis of CTCs utilize its Cell Enrichment and Extraction or CEE technology and the tests under development for the detection and analysis of ctDNA utilize the Company’s CEE-Selector technology each performed on a standard blood sample. The CEE technology is an internally developed microfluidics-based CTC capture and analysis platform with enabling features that change how CTC testing can be used by clinicians by providing real-time biomarker monitoring with a standard blood sample.